Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
XFOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.19 - $1.39
Previous CloseN/A
Volume769.31K
Average Volume (3M)1.77M
Market Cap
$36.47M
Enterprise Value$124.90M
Total Cash (Recent Filing)$3.88M
Total Debt (Recent Filing)$20.15M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
May 08, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding173,662,370
10 Day Avg. Volume1,983,332
30 Day Avg. Volume1,774,238
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)46.67
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap3.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit70.96
Enterprise Value/Ebitda-0.93
Forecast
1Y Price Target
$2.70Price Target Upside1250.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
X4 Pharmaceuticals News
PremiumCompany Announcements
X4 Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
X4 Pharmaceuticals Reports 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
CommercializationX4 entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of Xolremdi in Europe, Australia, and New Zealand, with potential E.U. approval in 1H26.
EarningsThe company reported total revenue of $1.4M, compared to the consensus estimate of $1.06M, and a net income of $0.20 per share, compared to the consensus estimated a net loss of $0.18 per share.
Strategic PartnershipsX4 is expected to receive an initial upfront payment of €28.5M and up to €226M in regulatory, commercial, and sales milestones from the agreement with Norgine.
Bears Say
ChallengesThe longer-than-expected time to diagnose and initiate therapy for new WHIM patients and the high commercial cost to onboard a patient are challenges faced by the company.
FinancingDespite the collaboration, additional capital is still considered necessary to provide sufficient runway to topline data from the P3 4WARD trial.
Market AdoptionMarket adoption of the drug has not been as robust as expected.
---
Ownership Overview
14.82% Insiders
7.41% Mutual Funds
31.82% Other Institutional Investors
37.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XFOR FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was $0.19 and its highest was $1.39 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
X4 Pharmaceuticals Inc’s market cap is $36.47M.
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is May 08, 2025 which is in 23 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on Mar 25, 2025. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.176 by -$0.024.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate is -0.12.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 173,662,370 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.176. Following the earnings report the stock price went down -13.333%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in XFOR
---
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.70 (1250.00% Upside)
$2.70 (1250.00% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.99%
12-Months-Change
Fundamentals
Return on Equity
-102.26%
Trailing 12-Months
Asset Growth
-0.55%
Trailing 12-Months
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc. (XFOR) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics aimed at treating rare diseases. The company's primary focus is on diseases characterized by disruptions in immune cell trafficking, including certain types of primary immunodeficiencies. X4's lead product candidate, mavorixafor, is being developed to treat a range of conditions linked to this mechanism, such as WHIM syndrome, a rare immune disorder.
---
XFOR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
X4 Pharmaceuticals showed strong progress with the launch of XOLREMDI and international expansion efforts. Positive clinical trial results and strategic restructuring indicate potential for future growth. However, the company faces challenges with net losses, market penetration, and adjustments in clinical trial protocols.Read More>---
XFOR Stock 12 Month Forecast
Average Price Target
$2.70
▲(1250.00% Upside)
Technical Analysis
Karyopharm Therapeutics
―
NRX Pharmaceuticals
―
Repare Therapeutics
―
Xilio Therapeutics
―
PepGen Inc.
―
Best Analysts Covering XFOR
1 Year
1 Year Success Rate
4/17 ratings generated profit
1 Year Average Return
-25.68%
reiterated a buy rating 22 days ago
Copying Leah R. Cann's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -25.68% per trade.
---